Literature DB >> 3579340

Livedo reticularis associated with increased titers of anticardiolipin antibodies in systemic lupus erythematosus.

C Weinstein, M H Miller, R Axtens, R Buchanan, G O Littlejohn.   

Abstract

Seventy-eight consecutive patients with systemic lupus erythematosus were assessed for the presence of livedo reticularis. The possible association of livedo reticularis with other clinical and laboratory features including anticardiolipin antibodies was explored. Thirty-eight patients had livedo reticularis. Four cases were severe, 11 moderate, and 23 mild. There was a statistically significant association between the combined moderate and severe livedo reticularis group and elevated levels of anticardiolipin antibodies. The recognized association of anticardiolipin antibodies with thrombotic events suggests a possible pathogenetic role. The presence or history of central nervous system disease, renal disease, vasculitis, or lupus inhibitor was significantly associated with the moderate and severe livedo reticularis group. Livedo reticularis may be a cutaneous marker for the later development of important systemic events in systemic lupus erythematosus.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3579340

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  6 in total

1.  A high-risk laboratory profile of antiphospholipid antibodies and thrombosis is associated with a large number of extra-criteria manifestations in obstetric antiphospholipid syndrome.

Authors:  Sebastián Udry; José Omar Latino; Cristina Belizna; Silvia Perés Wingeyer; Diego Santiago Fernández Romero; Gabriela de Larrañaga
Journal:  Immunol Res       Date:  2019-12       Impact factor: 2.829

Review 2.  [Lupus erythematosus. Wide range of symptoms through clinical variation, associated diseases and imitators].

Authors:  E Aberer
Journal:  Hautarzt       Date:  2010-08       Impact factor: 0.751

3.  Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder.

Authors:  C G Mackworth-Young; S Loizou; M J Walport
Journal:  Ann Rheum Dis       Date:  1989-05       Impact factor: 19.103

Review 4.  The 'antiphospholipid syndrome' and the 'lupus anticoagulant'.

Authors:  J S Cameron; G Frampton
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

5.  Cutaneous manifestations associated with antiphospholipid antibodies in patients with suspected primary antiphospholipid syndrome: a case-control study.

Authors:  L Naldi; F Locati; L Marchesi; S Cortelazzo; G Finazzi; M Galli; A Brevi; T Cainelli; T Barbui
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

6.  Significance of antibodies to cardiolipin in unselected patients with systemic lupus erythematosus: clinical and laboratory associations. The SLE Study Group.

Authors:  C Sachse; K Lüthke; K Hartung; M Fricke; B Liedvogel; J R Kalden; H H Peter; H J Lakomek; E Henkel; H Deicher
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.